People Briefs: EnteroMedics, Direct Flow Medical, Veracyte, VolitionRx, Nuvasive
This article was originally published in The Gray Sheet
EnteroMedics founder and CEO to retire, Direct Flow Medical appoints VP, regulatory and clinical affairs, Veracyte names chief medical officer, and more personnel updates from around the industry.
You may also be interested in...
Direct Flow Medical hopes it May 7 appointment of Daniel Lemaitre as CEO will elevate its competitive game against larger players in the transcatheter aortic valve replacement market.
The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.